Israel Biotech Fund
Israelibf.fund
Overview
Israel Biotech Fund invests exclusively in Israeli and Israeli related biotech companies at all development stages. The fund is committed to seeking high-value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotechnology companies. IBF provides its portfolio companies with hands-on guidance and the necessary resources for long-term sustainable growth.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Ukko | Jan 2026 | Series C | Lead |
| Cellyrix Therapeutics | Dec 2024 | Seed | Co-investor |
| Vensica Medical | Oct 2024 | VC Round | Lead |
| SpliSense | Apr 2024 | Grant | Co-investor |
| TenAces Biosciences | Jan 2024 | Seed | Co-investor |
Key People
Yuval Cabilly
Managing Partner
Ido Zairi
General Partner
Sarit Steinberg
Partner
Benjamin Maisano
Fund Advisor Investor
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
